In fact, even in those patients with no recognizable NF-κB-pathway mutations, MM cells constitutively engage these pathways via stimuli emanating from the tumor microenvironment (Hideshima et al., 2005, Staudt, 2010). The gene discussed is NFKB1; the disease is Miyoshi myopathy.